MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, MREO had -$7,009K decrease in cash & cash equivalents over the period. -$7,309K in free cash flow.

Cash Flow Overview

Change in Cash
-$7,009K
Free Cash flow
-$7,309K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-7,024 -27,503
Share-based compensation
1,712 4,343
Depreciation
39 82
Amortization of intangible assets
-183 224
Amortization of operating lease right-of-use assets
133 262
Change in fair value of warrants
-196 -315
Interest income
34 -
Non-cash interest expense
17 193
Foreign currency transaction loss
1,873 -8,091
Other income
300 -
Prepaid expenses and other current assets
164 155
Research and development incentives receivable
-1,661 -208
Accounts payable
-236 -1,589
Accrued expenses and other liabilities
-673 540
Operating lease liabilities
-188 -361
Net cash used in operating activities
-7,309 -15,980
Payments for intangible assets
0 300
Purchase of property and equipment
0 20
Proceeds from out-licensing
300 -
Net cash used in investing activities
300 -320
Proceeds from exercise of warrants
0 487
Proceeds from issuance of ordinary shares
0 0
Transaction costs on issuance of ordinary shares
0 199
Net cash provided by financing activities
0 288
(decrease)/increase in cash and cash equivalents
-7,009 -16,012
Cash and cash equivalents at beginning of period
69,802 -
Effect of exchange rate changes on cash
1,917 -
Cash and cash equivalents at end of period
48,698 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Mereo BioPharma Group plc (MREO)

Mereo BioPharma Group plc (MREO)